Fig. 2.

Baseline-adjusted office systolic blood pressure (SBP) and diastolic blood pressure (DBP) mean changes (and 95% confidence intervals) from baseline after 12 weeks of double-blind treatment with olmesartan medoxomil 10–40 mg (open bars) or ramipril 2.5–10 mg (grey bars) in the whole study population (n = 1426) and in high-risk subgroups. The numbers in parentheses indicate the number of subjects treated with olmesartan and ramipril, respectively. The statistical significance of between-treatment differences is indicated by asterisks (***p < 0.001, **p < 0.01).

Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, High Blood Pressure & Cardiovascular Prevention, Olmesartan vs. Ramipril in Elderly Hypertensive Patients: Review of Data from Two Published Randomized, Double-Blind Studies, Stefano Omboni, Ettore Malacco, Jean-Michel Mallion et al, 2014